Shots:
- JCR Pharmaceuticals & Modalis have reported successful validation of initial PoC to develop gene therapy targeting CNS disease and will advance to the next phase under a new joint agreement
- The new agreement aims at conducting preclinical studies for gene therapy using JCR’s BBB-crossing J-Brain Cargo tech and for gene therapy payload using Modalis’ CRISPR-GNDM epigenome modulation tech, which avoids DNA cleavage or alteration
- Initial agreement was signed in Dec 2023 to validate the CNS gene therapy delivery technology and developing an innovative IV-administered therapy to offer improved efficacy, safety, and minimal patient burden
Ref: BussinessWire | Image: Modalis & JCR Pharmaceuticals
Related News:- Modalis Therapeutics Unveils Epigenome Editing Therapy MDL-101 for Treatment of LAMA2-Deficient CMD
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
